CHFS HFU Header

Corridor Consults

Friday May 7, 2021

3:50 - 4:05 PM
Debate: Which Should be Started First, ARNI or SGLT2i? (Bi-Lilly)
Join us for a hot topic debate: What should be initiated first between a SGLT2i and ARNI? Two experts, two perspectives, one moderator to ensure you get clear information that can be applied into practice!
Jacob A. Udell, MD
Abhinav Sharma, MD
Shelley Zieroth, MD
3:50 - 4:05 PM
Overview of the 2021 CANM Cardiac Amyloid PYP Imaging Guidelines (Pfizer)
In this 15-minute session, Dr. Margot Davis and Dr. Jean-Luc Urbain will present a brief overview of the newly released guidelines by the Canadian Association of Nuclear Medicine (CANM) around nuclear imaging for cardiac amyloid. The speakers will present the guidelines’ highlights: patient selection, considerations around scintigraphy, interpretation of images, scoring systems, and treatment. This interactive session will allow you to exchange with the experts and ask your questions around the CANM guidelines.
Margot Davis, MD
Jean-Luc C. Urbain, MD
3:50 - 4:05 PM
What to Consider When Referring for Genetic Testing? (Akcea)
What should you consider before referring a patient for genetic testing? How should you manage the findings and what are the implications for patients and their families? Dr. Fine and Ms. Bolduc will answer all your pressing questions around the practical considerations of genetic testing!
Nowell M. Fine, MD
Nathalie Bolduc
7:35 - 7:50 PM
Clinical Applications of the 2021 CANM Cardiac Amyloid PYP Imaging Guidelines (Pfizer)
Learn more about the clinical applications of the CANM Cardiac Amyloid PYP Imaging guidelines with Dr. Nowell Fine and Dr. Cigdem Akincioglu. In this 15-minute interactive session, Dr. Fine will present the clinical considerations of nuclear imaging and how nuclear medicine fits into the management of patients with cardiac amyloidosis. Dr. Akincioglu will review imaging from select patient cases. Make sure to tune in to ask the experts your questions!
Nowell M. Fine MD
Cigdem Akincioglu, MD

Saturday May 8, 2021

11:20 - 11:35 AM
Does my Patient Have Worsening Heart Failure? Can it be Treated? (Bayer)
Dr. Ezekowitz and Dr. Gupta will answer the top 5 questions about worsening heart failure through a comprehensive discussion and lively exchange
Justin A. Ezekowitz
Anil Gupta, MD
11:20 - 11:35 AM
What can Ottawa and Alberta Agree On? Approaches to Drug Initiation in HFrEF (Novartis)
When treating heart failure, there is urgency to initiate the Big 4 (ARNI, BB, MRA, SGLT2i) as soon as possible. Dr. Mielniczuk and Dr. Howlett will provide real-lived experience around the timing of initiation, what has worked, what hasn’t, and will share those lessons with you.
Jonathan Howlett, MD
Lisa Mielniczuk, MD
11:20 - 11:35 AM
Is Titrating too Complex? Focusing on Optimized Results for Patients (AstraZeneca) with HFrEF
Dr. McKelvie will present a comprehensive and holistic approach for treating patients with heart failure, focusing on optimizing their treatment.
Robert McKelvie, MD
3:10 - 3:25 PM
Do You Know What Quality of Life Means for Your Patients with Heart Failure? (Bi-Lilly)
Dr. Howlett will discuss the different definitions of quality of life and the validity of the 6-minute walk test and highlight the importance of engaging your patient in a meaningful discussion about their needs and their objectives as a patient living with heart failure.
Jonathan Howlett, MD
3:10 - 3:25 PM
Screening Tool to Help Recognize Amyloidosis (Alnylam)
Dr. Fine will discuss patient questionnaires that can be used by cardiologists to help screen for signs and symptoms of amyloidosis to facilitate earlier disease recognition and diagnosis.
Nowell M. Fine MD
3:10 - 3:25 PM
Synergistic Role of Beta-Blockers and Ivabradine (Servier)
Join Dr. Serge Lepage in this interactive session to discuss the role of ivabradine for the treatment of HFrEF and assess the benefits of combination therapy for optimal heart rate control.
Serge Lepage, MD

 

Follow @CanHFSociety Along on Twitter

#HFUpdate